← Back to Search

Cannabinoid

Cannabinoid Therapy for Decision-Making in Substance Use Disorders

Phase < 1
Waitlist Available
Led By Michael J Wesley, PhD
Research Sponsored by Michael J. Wesley, PhD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up measured 2 times: baseline (0hr) and 3 hours (3hr) after capsule administration on each drug condition (0mg, 10mg, 30mg)
Awards & highlights

Study Summary

This trial will study how cannabis use disorder impacts decision making in adults, in hopes of better informing prevention and treatment efforts.

Who is the study for?
This trial is for young adults who regularly use cannabis and may have issues with decision-making due to this habit. Participants should have a Body Mass Index (BMI) of 30 or less. It's not suitable for individuals without habitual cannabis use problems.Check my eligibility
What is being tested?
The study is testing the effects of Marinol, a synthetic form of THC, and Transcranial Magnetic Stimulation (TMS), which uses magnetic fields to stimulate nerve cells in the brain, on decision-making in those with frequent cannabis use.See study design
What are the potential side effects?
Marinol can cause mood changes, dizziness, weakness, stomach pain, nausea, vomiting; TMS might lead to headache or discomfort at stimulation site. Both interventions could potentially affect cognitive functions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~measured 2 times: baseline (0hr) and 3 hours (3hr) after capsule administration on each drug condition (0mg, 10mg, 30mg)
This trial's timeline: 3 weeks for screening, Varies for treatment, and measured 2 times: baseline (0hr) and 3 hours (3hr) after capsule administration on each drug condition (0mg, 10mg, 30mg) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Alpha Learning Rate
Elasticity of Demand
Self-Report Subjective "High"
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Inhibitory TMSExperimental Treatment6 Interventions
Individuals assigned to this group will receive inhibitory (real and sham) TMS in combination with 0, 10, and 30mg THC.
Group II: Excitatory TMSExperimental Treatment6 Interventions
Individuals assigned to this group will receive excitatory (real and sham) TMS in combination with 0, 10, and 30mg THC.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Marinol 30Mg Capsule TMS Sham
2017
Completed Early Phase 1
~70
Marinol 10Mg Capsule TMS Sham
2017
Completed Early Phase 1
~70
Placebo TMS Sham
2017
Completed Early Phase 1
~70
Placebo TMS Real
2017
Completed Early Phase 1
~70

Find a Location

Who is running the clinical trial?

Michael J. Wesley, PhDLead Sponsor
National Institute on Drug Abuse (NIDA)NIH
2,468 Previous Clinical Trials
2,619,283 Total Patients Enrolled
Michael J Wesley, PhDPrincipal InvestigatorUniversity of Kentucky

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this medical experiment encompass elderly participants over the age of 75?

"This clinical trial is targeting young adults aged between 18 and 34."

Answered by AI

To what maladies is Transcranial Magnetic Stimulation regularly employed?

"Transcranial magnetic stimulation has been successfully used to both promote weight loss and alleviate the symptoms of various conditions, including unresponsiveness to regular medication or pharmacological treatment. Additionally, it can suppress a patient's appetite."

Answered by AI

Are there any other examples of research regarding Transcranial Magnetic Stimulation?

"Currently, the landscape of Transcranial magnetic stimulation studies includes 38 trials running in tandem. Of those clinical trails, 6 are Phase 3 with Belmont, Massachusetts being a hub for research on this intervention. Meanwhile there are 90 different locations that offer this treatment to participants."

Answered by AI

What are the criteria for individuals to qualify as participants in this experiment?

"This particular trial seeks 40 volunteers with a background in neuroscience, and are between 18-34 years of age. Moreover, applicants must have habitual cannabis usage troubles as well as remain within the acceptable BMI range (≤30)."

Answered by AI

Is it currently feasible to enroll in this medical study?

"Based on the clinicaltrials.gov listing, this study is currently recruiting trial participants; it was originally published in July of 2017 and recently revised in May of 2022."

Answered by AI

How many test subjects are enrolled in the present clinical trial?

"Affirmative. The clinicaltrial.gov page for this medical trial confirms that recruitment is underway, with the initial post dated July 15th 2017 and the most recent update taking place on May 9th 2022. A total of 40 patients need to be recruited from a single study site."

Answered by AI

Who else is applying?

What state do they live in?
Tennessee
How old are they?
18 - 65
What site did they apply to?
Neurobehavioral Systems Lab of the University of Kentucky College of Medicine
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Neural Mechanisms of Cannabinoid-impaired Decision-Making in Emerging Adults
Michael J. Wesley, PhD 2017. "Neural Mechanisms of Cannabinoid-impaired Decision-Making in Emerging Adults". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03944954.
~9 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top